“Delta NS1
Vaccine Platform”
Delta NS1 is a versatile and robust technology platform for broadly protective, self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain.
Vivaldi Biosciences is developing Delta NS1 vaccines for protection against epidemic and pandemic viral respiratory diseases.
Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.
Interferon is signaling protein in the body that acts as an early-warning system and triggers a broad-based immune response. Naturally occurring influenza viruses produce NS1 to block the body’s interferon response. We have deleted the NS1 gene from the Delta NS1 vector – so Delta NS1 based vaccines induce rather than inhibit interferon.
And Delta NS1-based vaccines are safe – they do not replicate and do not produce viral progeny. Individuals immunized with Delta NS1-based vaccines do not shed the vaccine virus. Safety, and lack of replication and shedding of Delta NS1-based vaccines have been demonstrated in four clinical trials.
The Delta NS1 vaccine vector can stably express at high levels foreign proteins and antigens from other viruses and bacteria, enabling development of a broad array of prophylactic vaccines for infectious diseases, and therapeutic vaccines for cancer. Delta NS1 is the backbone for our Phase 2 DeltaFLU universal influenza vaccine and our preclinical Covid-19 / Universal Influenza Vaccine.
DeltaFLU
Universal Influenza Vaccine
Delta-19
Covid-19 + Universal Influenza
Combination Vaccine
Delivered into the nasal passages in a gentle spray, Delta NS1 vaccines introduce viral antigens that stimulate multiple components of the immune system to achieve a broadly protective immune response. Delta NS1 vaccines are unique in their ability to induce interferon, a signaling protein in the body that acts as an early-warning system and triggers a broad-based immune response that protects against viruses entering the nasal passages, and activates systemic antibody and cell-based immunity.
Deletion of the NS1 gene also makes Delta NS1 vaccine strains replication-deficient. Because of this, Delta NS1 strains cannot cause disease and do not produce viral progeny. Individuals immunized with Delta NS1 vaccines do not shed the vaccine virus. These are important safety aspects of the Delta NS1 approach, and significant advantages over live vaccines that are able to replicate.
